New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
34th Annual Global Healthcare Conference is being held in Boston on March 3-5 with webcasted company presentations to begin on March 4 at 8:00 am; not all company presentations may be webcasted. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
June 16, 2015
10:29 EDTMYL, TEVAGeneric drugs may be targets of congressional price probe, Bloomberg says
In addition to branded drugs that were cited for "staggering" price increases in a congressional probe on drug prices being led by U.S. Senator Bernie Saunders, generic drug makers may also be targeted, stated Bloomberg Intelligence. Data show some generics, including clomipramine hydrochloride and tetracycline, have seen "aggressive" quarterly price increases, the report noted. Generic drug makers that could be caught up in the probe include Mallinckrodt (MNK), Teva (TEVA), Novartis' (NVS) Sandoz unit, Mylan (MYL), Taro Pharmaceutical (TARO) and Teva (TEVA). Mallinckrodt shares are down about 4% in early trading.
09:21 EDTMYLMylan issues statement regarding Abbott's support for Perrigo transaction
Subscribe for More Information
09:10 EDTMYLAbbott confirms support for Mylan's proposed acquisition of Perrigo
Abbott (BT) confirmed its continued support for Mylan (MYL) N.V's growth strategy by stating its intent to vote its 14.5% stake in Mylan in favor of Mylan's proposed acquisition of Perrigo (PRGO). "We chose Mylan to acquire our developed markets branded generics pharmaceuticals because its scale and breadth across critical distribution channels, broad and diverse portfolio, and commitment to patients and product quality strongly positions it for success in the years to come," said Abbott. "As both Mylan's largest shareholder and its partner through our continued manufacturing relationships, Abbott has considered the entire situation and we believe Mylan's standalone strategy and acquisition of Perrigo will further enhance its platform, is strategically compelling, value enhancing for shareholders, and offers a clear path to completion. In light of these factors, we will be voting in favor of the Perrigo transaction."
09:06 EDTXOMAXOMA receives ODD for XOMA 358 from FDA
Subscribe for More Information
08:54 EDTMYLPulmatrix enter into development agreement with Mylan for PUR0200
Pulmatrix (PULM) announced that it has entered into an ex-U.S. development agreement with Mylan (MYL). The agreement is for PUR0200, a clinical stage bronchodilator therapy being studied for chronic obstructive pulmonary disease, or COPD, and the first small molecule formulation from the company's novel iSPERSE inhaled dry powder technology. PUR0200 is under development as a once-daily therapy in a capsule-based dry powder inhaler, or DP. Under the terms of the agreement, Pulmatrix will lead the development work and pharmacokinetic clinical study with collaborative support from Mylan. Mylan has retained an option for PUR0200 ex-U.S. based on successful completion of the clinical study. Financial terms of the agreement are confidential.
08:05 EDTTEVATeva reports ARM-TD study meets primary endpoint
Teva Pharmaceutical (TEVA) announced positive top-line results from the pivotal clinical study Aim to Reduce Movements in Tardive Dyskinesia, or ARM-TD, designed to evaluate the efficacy of SD-809 in the treatment of moderate to severe tardive dyskinesia. Top-line data showed that the study met its primary endpoint and demonstrated a positive trend in all secondary endpoints. The primary endpoint of ARM-TD was the change in the Abnormal Involuntary Movement Scale, or AIMS, from baseline to end of therapy, assessed by blinded centralized video rating. The study results show patients taking SD-809 achieved an improvement of 3.0 points on the AIMS score from baseline to end of therapy compared to 1.6 points in placebo for a clinically meaningful effect. Study results also demonstrated a favorable safety and tolerability profile of SD-809. Fewer patients taking SD-809 than placebo experienced serious adverse events. Three patients discontinued from the study for adverse events. For all other side effects reported in the study, rates in the SD-809 group were similar or lower than the placebo group. Further analysis of the additional data from the study is ongoing and details will be shared at future medical meetings and through peer-reviewed publication, the company said. SD-809 became part of Teva’s central nervous system product portfolio with the acquisition of Auspex Pharmaceuticals in May.
07:31 EDTTEVAEagle Pharmaceuticals price target raised to $95 from $65 at Cantor
Subscribe for More Information
June 15, 2015
11:40 EDTBMYNCCN update on NSCLC important for Bristol-Myers, says Morgan Stanley
Morgan Stanley noted that the National Comprehensive Cancer Network, or NCCN, just updated its guidelines for the treatment of NSCLC to include Bristol-Myers' Opdivo in second-line non-squamous and squamous non-small cell lung cancer without PD-L1 testing, which the firm said is important news since the company hasn't filed for non-squamous approval with the FDA yet. Morgan Stanley maintained its Opdivo projections and keeps its Overweight rating on the stock.
11:26 EDTBMYBristol-Myers mentioned positively at Morgan Stanley
Subscribe for More Information
10:26 EDTBLUEbluebird bio price target raised to $241 on LentiGlobin data at BofA/Merrill
BofA/Merrill raised bluebird's price target to $241 from $214 citing impressive LentiGlobin data.
09:19 EDTALXN, AEGRBiotech Industry Organization to hold a conference
BIO 2015 is being held in Philadelphia on June 15-18.
09:16 EDTTEVAInternational Parkinson & Movement Disorder Society to hold a conference
9th International Congress of Parkinson's Disease and Movement Disorders is being held in San Diego, CA on June 14-18.
08:02 EDTTEVATeva announces FDA acceptance of BLA for Reslizumab
Teva Pharmaceutical Industries announced that the FDA has accepted for review the Biologics License Application for reslizumab, the company’s investigational humanized monoclonal antibody which targets interleukin-5, for the treatment of inadequately controlled asthma in adult and adolescent patients with elevated blood eosinophils, despite an inhaled corticosteroid based regimen. The BLA for reslizumab includes data from Teva’s Phase III BREATH clinical trial program. The program consisted of four separate placebo-controlled Phase III trials involving more than 1,700 adult and adolescent asthma patients with elevated blood eosinophils, whose symptoms were inadequately controlled with inhaled corticosteroid-based therapies. Results from these studies demonstrated that reslizumab, in comparison to placebo, reduced asthma exacerbation rates by at least half and provided significant improvement in lung function and other secondary measures of asthma control when added to an existing ICS-based therapy. Common adverse events in the reslizumab treatment group were comparable to placebo and included worsening of asthma, nasopharyngitis, upper respiratory infections, sinusitis, influenza and headache. Two anaphylactic reactions were reported and resolved following medical treatment at the study site.
08:00 EDTBMRNBioMarin risk/reward positive into dwarfism data, says Leerink
After speaking with specialists, Leerink continues to see a positive risk/reward for BioMarin into the BMN-111 for dwarfism data by the end of Q2. The company's goal of at least a 50% improvement in height velocity translates into a "relatively small" addition in stature of just 2 centimeters a year, the firm points out. It reiterates an Outperform rating on BioMarin with a $136 price target.
07:39 EDTBLUEbluebird bio price target raised to $230 from $205 at SunTrust
Subscribe for More Information
07:31 EDTBLUEbluebird bio names Philip Gregory as Chief Scientific Officer
Subscribe for More Information
07:23 EDTBLUEbluebird bio price target raised to $244 from $200 at JPMorgan
Subscribe for More Information
06:23 EDTBLUEbluebird bio to host conference call
Subscribe for More Information
06:02 EDTMYL, TEVATeva raises stake in Mylan to almost 3.5%, Globes reports
Subscribe for More Information
05:50 EDTBLUEbluebird bio should rally on data update, says Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use